^
    9d
    CARO: Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients (clinicaltrials.gov)
    P=N/A, N=359, Completed, iOMEDICO AG | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib
    13d
    Home Based Daratumumab Administration for Patients With Multiple Myeloma (clinicaltrials.gov)
    P4, N=20, Completed, Thomas Jefferson University | Phase classification: P1 --> P4
    Phase classification
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    14d
    A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=75, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Sep 2026 --> May 2025
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib
    15d
    Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=61, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial primary completion date
    |
    lenalidomide • Sarclisa (isatuximab-irfc)
    16d
    Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy (clinicaltrials.gov)
    P=N/A, N=450, Recruiting, Brigham and Women's Hospital | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial primary completion date
    |
    Darzalex (daratumumab)
    25d
    AQUARIUS: A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=151, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2026 --> May 2025
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    26d
    Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group. (PubMed, Int J Hematol)
    Stratifying patients with MM based on myeloma cell maturity provides meaningful information for choosing the best treatment strategy and improving patient outcomes.
    Journal
    |
    ITGA5 (Integrin Subunit Alpha 5)
    |
    lenalidomide • bortezomib • Darzalex (daratumumab)
    29d
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Oct 2025 --> Apr 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • maplirpacept (TTI-622)
    1m
    Palatal Solitary Plasmacytoma: A Case Report on Post-radiotherapy Challenges. (PubMed, Cancer Diagn Progn)
    At the patient's request, six cycles of systemic chemotherapy with daratumumab, lenalidomide, and dexamethasone (DRd) were administered, leading to further shrinkage without complete response. This rare case of solitary plasmacytoma showed residual disease post definitive radiotherapy. In those residual tumors, close long-term monitoring is crucial.
    Journal
    |
    SDC1 (Syndecan 1) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4)
    |
    lenalidomide • Darzalex (daratumumab)
    1m
    NCI-2022-03039: Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Feb 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Darzalex (daratumumab)
    1m
    Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders (clinicaltrials.gov)
    P1/2, N=30, Recruiting, University of Maryland, Baltimore | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)